Review article: The economic impact of the irritable bowel syndrome

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 9, 2014, Pages 1023-1034

  Canavan, C ^a   West, J ^a   Card, T ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; LAXATIVE; SPASMOLYTIC AGENT;

ABDOMINAL SURGERY; ABSENTEEISM; CAREGIVER BURDEN; DIAGNOSTIC TEST; DRUG COST; EMERGENCY CARE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HEALTH INSURANCE; HUMAN; INCOME; IRRITABLE COLON; PRIMARY MEDICAL CARE; PRODUCTIVITY; QUALITY OF LIFE; REVIEW; SECONDARY HEALTH CARE; SOCIAL LIFE; SOCIOECONOMICS; SYSTEMATIC REVIEW; CHRONIC DISEASE; ECONOMICS; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; INTERNATIONAL COOPERATION; IRRITABLE BOWEL SYNDROME; LIFE EXPECTANCY; PATHOPHYSIOLOGY; TRENDS; UTILIZATION;

ABSENTEEISM; CHRONIC DISEASE; DELIVERY OF HEALTH CARE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HEALTH RESOURCES; HUMANS; INTERNATIONALITY; IRRITABLE BOWEL SYNDROME; LIFE EXPECTANCY; QUALITY OF LIFE;

EID: 84907979161     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12938     Document Type: Review

References (68)

1. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol 2014; 6: 71-80.
2. Dean BB, Aguilar D, Barghout V, et al. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care 2005; 11(1 Suppl.): S17-26.
3. Simrén M, Brazier J, Coremans G, et al. Quality of life and illness costs in irritable bowel syndrome. Digestion 2004; 69: 254-61.
4. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712-21.
5. Luce BR, Simpson K. Methods of costeffectiveness analysis: areas of consensus and debate. Clin Ther 1995; 17: 109-25.
6. Wells NE, Hahn BA, Whorwell PJ. Clinical economics review: irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 1019-30.
7. Cash B. Economic impact of irritable bowel syndrome: what does the future hold? Am J Manag Care 2005; 11(1 Suppl.): S4-6.
8. Inadomi JM, Fennerty MB, Bjorkman D. Systematic review: the economic impact of irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18: 671-82.
9. Claxton KP, Sculpher MJ, Culyer AJ. Mark versus Luke? Appropriate methods for the evaluation of public health interventioan. CHE Res Pap 2007; 31: 20.
10. El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther 2002; 16: 1171-85.
11. Bushnell DM, Martin ML, Ricci J-F, Bracco A. Performance of the EQ-5D in patients with irritable bowel syndrome. Value Health 2006; 9: 90-7.
12. Weinstein MC, Manning WG. Theoretical issues in cost-effectiveness analysis. J Health Econ 1997; 16: 121-8.
13. EuroQol Group. In: Szende A, Oppe M, Devlin N, eds. EQ-5D Value Sets. Inventory, Comparative Review and User Guide, Vol. 2. Dordrecht: Springer, 2007.
14. Spiegel B, Harris L, Lucak S, et al. Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort. Am J Gastroenterol 2009; 104: 1984-91.
15. Hulisz D. The burden of illness of irritable bowel syndrome: current challenges and hope for the future. J Manag Care Pharm 2004; 10: 299-309.
16. Smith GD, Steinke DT, Kinnear M, Penny KI, Pathmanathan N, Penman ID. A comparison of irritable bowel syndrome patients managed in primary and secondary care: the Episode IBS study. Br J Gen Pract 2004; 54: 503-7.
17. Paré P, Gray J, Lam S, et al. Healthrelated quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Ther 2006; 28: 1726-35.
18. Lee V, Guthrie E, Robinson A, et al. Functional bowel disorders in primary care: factors associated with healthrelated quality of life and doctor consultation. J Psychosom Res 2008; 64: 129-38.
19. Bushnell DM, Reilly MC, Galani C, et al. Validation of electronic data capture of the Irritable Bowel Syndrome-Quality of Life Measure, the Work Productivity and Activity Impairment Questionnaire for Irritable Bowel Syndrome and the EuroQol. Value Health 2006; 9: 98-105.
20. Stark RG, Reitmeir P, Leidl R, König H-H. Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany. Inflamm Bowel Dis 2010; 16: 42-51.
21. König H-H, Ulshöfer A, Gregor M, et al. Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002; 14: 1205-15.
22. Gray AM, Papanicolas IN. Impact of symptoms on quality of life before and after diagnosis of coeliac disease: results from a UK population survey. BMC Health Serv Res 2010; 10: 105.
23. Färkkilä N, Sintonen H, Saarto T, et al. Health-related quality of life in colorectal cancer. Colorectal Dis 2013; 15: e215-22. doi:10.1111/codi.12143
24. Minocha A, Johnson WD, Abell TL, Wigington WC. Prevalence, sociodemography, and quality of life of older versus younger patients with irritable bowel syndrome: a populationbased study. Dig Dis Sci 2006; 51: 446-53.
25. Akehurst RL, Brazier JE, Mathers N, et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics 2002; 20: 455-62.
26. Silk DB. Impact of irritable bowel syndrome on personal relationships and working practices. Eur J Gastroenterol Hepatol 2001; 13: 1327-32.
27. Levy RL, Von Korff M, Whitehead WE, et al. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001; 96: 3122-9.
28. Williams RE, Black CL, Kim H-Y, et al. Determinants of healthcare-seeking behaviour among subjects with irritable bowel syndrome. Aliment Pharmacol Ther 2006; 23: 1667-75.
29. Talley NJ, Zinsmeister AR, Melton LJ. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol 1995; 142: 76-83.
30. Ford AC, Forman D, Bailey AG, Axon ATR, Moayyedi P. Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol 2008; 103: 1229-39.
31. Müller-Lissner SA, Pirk O. Irritable bowel syndrome in Germany. A cost of illness study. Eur J Gastroenterol Hepatol 2002; 14: 1325-9.
32. Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995; 109: 1736-41.
33. Bentkover JD, Field C, Greene EM, Plourde V, Casciano JP. The economic burden of irritable bowel syndrome in Canada. Can J Gastroenterol 1999; 13 (Suppl. A): 89A-96A.
34. Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut 2000; 46: 78-82.
35. Longstreth GF, Wilson A, Knight K, et al. Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol 2003; 98: 600-7.
36. Longstreth GF, Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology 2004; 126: 1665-73.
37. Hungin APS, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects. Aliment Pharmacol Ther 2003; 17: 643-50.
38. Kennedy TM, Jones RH. Epidemiology of cholecystectomy and irritable bowel syndrome in a UK population. Br J Surg 2000; 87: 1658-63.
39. Agréus L. Socio-economic factors, health care consumption and rating of abdominal symptom severity. A report from the abdominal symptom study. Fam Pract 1993; 10: 152-63.
40. Lieberman DA, Holub J, Eisen G, Kraemer D, Morris CD. Utilization of colonoscopy in the United States: results from a national consortium. Gastrointest Endosc 2005; 62: 875-83.
41. Chey WD, Nojkov B, Rubenstein JH, Dobhan RR, Greenson JK, Cash BD. The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. Am J Gastroenterol 2010; 105: 859-65.
42. Spiegel BMR, Gralnek IM, Bolus R, et al. Is a negative colonoscopy associated with reassurance or improved health-related quality of life in irritable bowel syndrome? Gastrointest Endosc 2005; 62: 892-9.
43. Martin R, Barron JJ, Zacker C. Irritable bowel syndrome: toward a cost-effective management approach. Am J Manag Care 2001; 7(8 Suppl.): S268-75.
44. Spiegel BMR, Farid M, Esrailian E, Talley J, Chang L. Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol 2010; 105: 848-58.
45. Begtrup LM, Engsbro AL, Kjeldsen J, et al. A positive diagnostic strategy is noninferior to a strategy of exclusion for patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2013; 11: 956-62.
46. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104(Suppl. S1): S1-35.
47. Spiller R, Aziz Q, Creed F, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007; 56: 1770-98.
48. Talley NJ, Boyce PM, Jones M. Predictors of health care seeking for irritable bowel syndrome: a population based study. Gut 1997; 41: 394-8.
49. Hungin AP, Chang L, Locke GR, Dennis EH, Barghout V. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther 2005; 21: 1365-75.
50. Koloski NA, Talley NJ, Huskic SS, Boyce PM. Predictors of conventional and alternative health care seeking for irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2003; 17: 841-51.
51. Spiegel BMR, Kanwal F, Naliboff B, Mayer E. The impact of somatization on the use of gastrointestinal healthcare resources in patients with irritable bowel syndrome. Am J Gastroenterol 2005; 100: 2262-73.
52. Ricci J, Jhingran P. Costs of care for irritable bowel syndrome in managed care. JCOM 2000; 7: 23-8.
53. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122: 1500-11.
54. Le Pen C, Ruszniewski P, Gaudin AF, et al. The burden cost of French patients suffering from irritable bowel syndrome. Scand J Gastroenterol 2004; 39: 336-43.
55. Roshandel D, Rezailashkajani M, Shafaee S, Zali MR. A cost analysis of functional bowel disorders in Iran. Int J Colorectal Dis 2007; 22: 791-9.
56. Johansson PA, Farup PG, Bracco A, Vandvik PO. How does comorbidity affect cost of health care in patients with irritable bowel syndrome? A cohort study in general practice. BMC Gastroenterol 2010; 10: 31.
57. Flik CE, Laan W, Smout A, deWit NJ. Medical costs of Irritable Bowel Syndrome patients referred to secondary care in the Netherlands. UEGW, Berlin, Germany, 2012.
58. Kennedy TM, Jones RH, Hungin AP, O'flanagan H, Kelly P. Irritable bowel syndrome, gastro-oesophageal reflux, and bronchial hyper-responsiveness in the general population. Gut 1998; 43: 770-4.
59. Hillilä MT, Siivola MT, Färkkilä MA. Comorbidity and use of healthcare services among irritable bowel syndrome sufferers. Scand J Gastroenterol 2007; 42: 799-806.
60. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002; 122: 1140-56.
61. Patel RP, Petitta A, Fogel R, Peterson E, Zarowitz BJ. The economic impact of irritable bowel syndrome in a managed care setting. J Clin Gastroenterol 2002; 35: 14-20.
62. Hahn BA, Kirchdoerfer LJ, Fullerton S, Mayer E. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther 1997; 11: 553-9.
63. Reilly MC, Bracco A, Ricci J-F, Santoro J, Stevens T. The validity and accuracy of the Work Productivity and Activity Impairment questionnaire-irritable bowel syndrome version (WPAI:IBS). Aliment Pharmacol Ther 2004; 20: 459-67.
64. Leong SA, Barghout V, Birnbaum HG, et al. The economic consequences of irritable bowel syndrome: a US employer perspective. Arch Intern Med 2003; 163: 929-35.
65. Wong RK, Drossman DA, Weinland SR, et al. Partner burden in irritable bowel syndrome. Clin Gastroenterol Hepatol 2013; 11: 151-5.
66. Asare F, Störsrud S, Simrén M. Meditation over medication for irritable bowel syndrome? On exercise and alternative treatments for irritable bowel syndrome. Curr Gastroenterol Rep 2012; 14: 283-9.
67. Creed F. Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. Ann Intern Med 2001; 134(9: Part 2):860.
68. Nyrop KA, Palsson OS, Levy RL, et al. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. Aliment Pharmacol Ther 2007; 26: 237-48.